VRXA
Veraxa Biotech AG
Price Chart
Latest Quote
$2.18
+0.13 (+6.34%)
Current Price
| Previous Close | $2.05 |
| Open | $2.09 |
| Day High | $2.21 |
| Day Low | $2.01 |
| Volume | 253,759 |
Stock Information
| Shares Outstanding | 141.41M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $308.27M |
| EPS (TTM) | $-0.58 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider Ownership | 71.15% |
| Institutional Ownership | 11.34% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $2.48 |
| SMA50 | $8.28 |
| SMA200 | $10.30 |
| RSI | 47.72 |
| ATR | 0.3953 |
| Short Ratio | 0.26 |
| Rel Volume | 0.23 |
Performance History
| Week | -0.91% |
| Month | -76.96% |
| Quarter | -83.30% |
| 6 Months | -79.51% |
| YTD | -79.55% |
| Year | -79.06% |
| 10 Years | -78.13% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $2.18 | 254,000 |
| 2026-07-16 | $2.05 | 114,700 |
| 2026-07-15 | $2.12 | 179,600 |
| 2026-07-14 | $2.09 | 373,900 |
| 2026-07-13 | $2.14 | 556,900 |
| 2026-07-10 | $2.20 | 504,800 |
| 2026-07-09 | $2.48 | 695,300 |
| 2026-07-08 | $2.76 | 1,856,400 |
| 2026-07-07 | $3.03 | 6,195,400 |
| 2026-07-06 | $2.19 | 1,037,000 |
| 2026-07-02 | $2.04 | 4,975,200 |
| 2026-07-01 | $1.73 | 935,200 |
| 2026-06-30 | $1.88 | 353,000 |
| 2026-06-29 | $2.17 | 197,900 |
| 2026-06-26 | $2.32 | 218,200 |
| 2026-06-25 | $2.35 | 480,600 |
| 2026-06-24 | $2.30 | 812,100 |
| 2026-06-23 | $2.91 | 801,600 |
| 2026-06-22 | $4.14 | 499,400 |
| 2026-06-18 | $4.48 | 772,300 |
About Veraxa Biotech AG
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.
đ° Latest News
The Cancer Therapy Strategy VERAXA Is Betting the Company On
Exec Edge âĸ 2026-07-06T16:00:53Z
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone
Exec Edge âĸ 2026-07-02T22:40:48Z
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development
Exec Edge âĸ 2026-06-24T18:15:00Z
VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026
Exec Edge âĸ 2026-06-18T14:34:10Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Reconciled Cost Of Revenue | $132,636 | $0 | - |
| Cost Of Revenue | $7,965 | $0 | - |
| Total Revenue | $23,426 | $0 | $0 |
| Operating Revenue | $23,426 | $0 | $0 |
| Expenses | |||
| Interest Expense | $3,552 | $291 | $1,090 |
| Total Expenses | $66,240,001 | $28,917,881 | $16,659,993 |
| Other Income Expense | $-786,466 | $164,427 | $-995,225 |
| Other Non Operating Income Expenses | $54,247 | $14,811 | $54,349 |
| Net Non Operating Interest Income Expense | $-3,552 | $-291 | $-1,090 |
| Interest Expense Non Operating | $3,552 | $291 | $1,090 |
| Operating Expense | $66,232,036 | $28,917,881 | $16,659,993 |
| Selling And Marketing Expense | $6,948,456 | $3,635,658 | $2,379,930 |
| General And Administrative Expense | $46,922,232 | $17,095,133 | $8,168,348 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-66,613,990 | $-28,132,971 | $-16,544,238 |
| Net Interest Income | $-3,552 | $-291 | $-1,090 |
| Normalized Income | $-65,778,203 | $-28,279,357 | $-15,560,771 |
| Net Income From Continuing And Discontinued Operation | $-66,613,990 | $-28,132,971 | $-16,544,238 |
| Total Operating Income As Reported | $-66,216,575 | $-28,917,881 | $-16,659,993 |
| Net Income Common Stockholders | $-66,613,990 | $-28,132,971 | $-16,544,238 |
| Net Income | $-66,613,990 | $-28,132,971 | $-16,544,238 |
| Net Income Including Noncontrolling Interests | $-66,613,990 | $-28,132,971 | $-16,544,238 |
| Net Income Continuous Operations | $-66,613,990 | $-28,132,971 | $-16,544,238 |
| Pretax Income | $-67,006,593 | $-28,753,745 | $-17,656,308 |
| Special Income Charges | $-799,168 | $-474,538 | $0 |
| Operating Income | $-66,216,575 | $-28,917,881 | $-16,659,993 |
| Depreciation Amortization Depletion Income Statement | $2,097,225 | $1,876,482 | $1,850,183 |
| Depreciation And Amortization In Income Statement | $2,097,225 | $1,876,482 | $1,850,183 |
| Gross Profit | $15,461 | $0 | - |
| Per Share | |||
| Diluted EPS | - | $-0.20 | $-0.12 |
| Basic EPS | - | $-0.20 | $-0.12 |
| Other | |||
| Tax Effect Of Unusual Items | $-4,926 | $3,230 | $-66,107 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-64,065,103 | $-27,026,588 | $-14,755,461 |
| Total Unusual Items | $-840,713 | $149,616 | $-1,049,574 |
| Total Unusual Items Excluding Goodwill | $-840,713 | $149,616 | $-1,049,574 |
| Reconciled Depreciation | $1,972,554 | $1,876,482 | $1,850,183 |
| EBITDA (Bullshit earnings) | $-64,905,816 | $-26,876,972 | $-15,805,035 |
| EBIT | $-67,003,041 | $-28,753,454 | $-17,655,218 |
| Diluted NI Availto Com Stockholders | $-66,613,990 | $-28,132,971 | $-16,544,238 |
| Tax Provision | $-392,603 | $-620,774 | $-1,112,070 |
| Other Special Charges | $799,168 | $474,538 | - |
| Gain On Sale Of Security | $-41,545 | $624,154 | $-1,049,574 |
| Research And Development | $10,264,123 | $6,310,608 | $4,261,532 |
| Selling General And Administration | $53,870,688 | $20,730,791 | $10,548,278 |
| Other Gand A | $46,922,232 | $17,095,133 | $8,168,348 |
| Diluted Average Shares | - | $141,407,813 | $141,407,813 |
| Basic Average Shares | - | $141,407,813 | $141,407,813 |
Fetched: 2026-07-09
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $-90,522,838 | $-45,279,204 | $-22,796,177 |
| Total Assets | $80,820,364 | $84,766,624 | $91,936,907 |
| Total Non Current Assets | $77,935,781 | $79,160,298 | $80,058,650 |
| Non Current Accounts Receivable | $70,718 | - | - |
| Goodwill And Other Intangible Assets | $74,756,691 | $76,334,020 | $77,923,921 |
| Other Intangible Assets | $51,907,963 | $53,485,292 | $55,075,193 |
| Current Assets | $2,884,583 | $5,606,326 | $11,878,257 |
| Other Current Assets | $100,243 | $68,814 | $268,273 |
| Receivables | $1,170,351 | $174,874 | $257,761 |
| Other Receivables | $1,111,424 | $153,606 | $257,761 |
| Cash Cash Equivalents And Short Term Investments | $1,613,989 | $5,362,638 | $11,352,223 |
| Cash And Cash Equivalents | $1,613,989 | $5,362,638 | $11,352,223 |
| Debt | |||
| Total Debt | $2,140,648 | $864,485 | $0 |
| Long Term Debt And Capital Lease Obligation | $883,553 | $708,082 | $0 |
| Current Debt And Capital Lease Obligation | $1,257,095 | $156,403 | - |
| Current Debt | $1,000,000 | - | - |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $96,586,511 | $53,711,808 | $36,809,163 |
| Total Non Current Liabilities Net Minority Interest | $89,972,701 | $51,165,666 | $35,201,605 |
| Other Non Current Liabilities | $2,898,873 | $2,099,705 | $1,625,167 |
| Non Current Deferred Liabilities | $14,440,732 | $15,165,086 | $15,791,518 |
| Non Current Deferred Taxes Liabilities | $14,440,732 | $15,165,086 | $15,791,518 |
| Current Liabilities | $6,613,810 | $2,546,142 | $1,607,558 |
| Other Current Liabilities | $1,290,160 | $98,846 | $101,492 |
| Current Deferred Liabilities | $1,026,917 | $546,754 | $598,310 |
| Current Deferred Taxes Liabilities | $535,548 | $427,592 | $390,729 |
| Current Notes Payable | $1,000,000 | $0 | - |
| Payables And Accrued Expenses | $1,850,601 | $742,261 | $907,756 |
| Payables | $1,390,932 | $488,543 | $611,575 |
| Accounts Payable | $1,390,932 | $488,543 | $611,575 |
| Equity | |||
| Common Stock Equity | $-15,766,147 | $31,054,816 | $55,127,744 |
| Total Equity Gross Minority Interest | $-15,766,147 | $31,054,816 | $55,127,744 |
| Stockholders Equity | $-15,766,147 | $31,054,816 | $55,127,744 |
| Gains Losses Not Affecting Retained Earnings | $67,961,126 | $48,736,977 | $45,449,910 |
| Other Equity Adjustments | $67,961,126 | $48,736,977 | $45,449,910 |
| Retained Earnings | $-98,478,340 | $-31,864,350 | $-3,731,379 |
| Other | |||
| Ordinary Shares Number | $141,407,813 | $141,407,813 | $141,407,813 |
| Share Issued | $141,407,813 | $141,407,813 | $141,407,813 |
| Tangible Book Value | $-90,522,838 | $-45,279,204 | $-22,796,177 |
| Invested Capital | $-14,766,147 | $31,054,816 | $55,127,744 |
| Working Capital | $-3,729,227 | $3,060,184 | $10,270,699 |
| Capital Lease Obligations | $1,140,648 | $864,485 | $0 |
| Total Capitalization | $-15,766,147 | $31,054,816 | $55,127,744 |
| Capital Stock | $14,751,067 | $14,182,189 | $13,409,213 |
| Common Stock | $14,751,067 | $14,182,189 | $13,409,213 |
| Non Current Accrued Expenses | $71,749,543 | $33,192,793 | $17,784,920 |
| Long Term Capital Lease Obligation | $883,553 | $708,082 | $0 |
| Current Deferred Revenue | $491,369 | $119,162 | $207,581 |
| Current Capital Lease Obligation | $257,095 | $156,403 | $0 |
| Current Provisions | $1,189,037 | $1,001,878 | - |
| Current Accrued Expenses | $459,669 | $253,718 | $296,181 |
| Goodwill | $22,848,728 | $22,848,728 | $22,848,728 |
| Net PPE | $3,108,372 | $2,826,278 | $2,134,729 |
| Accumulated Depreciation | $-1,431,115 | $-1,036,714 | $-746,966 |
| Gross PPE | $4,539,487 | $3,862,992 | $2,881,695 |
| Construction In Progress | $215,507 | $7,730 | $7,730 |
| Other Properties | $1,123,395 | $864,486 | - |
| Machinery Furniture Equipment | $3,200,585 | $2,990,776 | $2,873,965 |
| Duefrom Related Parties Current | $58,927 | $21,268 | $0 |
Fetched: 2026-07-09
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-10,339,507 | $-7,841,270 | $-7,500,125 |
| Operating Activities | |||
| Operating Cash Flow | $-9,902,331 | $-7,720,393 | $-7,267,818 |
| Cash Flow From Continuing Operating Activities | $-9,902,329 | $-7,720,393 | $-7,267,818 |
| Operating Gains Losses | $-59,251 | $-704,729 | $508,033 |
| Investing Activities | |||
| Capital Expenditure | $-437,176 | $-120,877 | $-232,307 |
| Investing Cash Flow | $-437,176 | $-120,877 | $-1,016,431 |
| Cash Flow From Continuing Investing Activities | $-437,176 | $-120,877 | $-1,016,431 |
| Financing Activities | |||
| Issuance Of Capital Stock | $5,755,498 | $1,851,685 | $12,536,908 |
| Financing Cash Flow | $6,590,858 | $1,851,685 | $12,536,908 |
| Cash Flow From Continuing Financing Activities | $6,590,858 | $1,851,685 | $12,536,908 |
| Net Common Stock Issuance | $5,755,498 | $1,851,685 | $12,536,908 |
| Common Stock Issuance | $5,755,498 | $1,851,685 | $12,536,908 |
| Other | |||
| Repayment Of Debt | $-164,640 | $0 | - |
| Issuance Of Debt | $1,000,000 | $0 | - |
| End Cash Position | $1,613,989 | $5,362,638 | $11,352,223 |
| Beginning Cash Position | $5,362,638 | $11,352,223 | $7,099,564 |
| Changes In Cash | $-3,748,649 | $-5,989,585 | $4,252,659 |
| Net Issuance Payments Of Debt | $835,360 | $0 | - |
| Net Short Term Debt Issuance | $1,000,000 | $0 | - |
| Short Term Debt Issuance | $1,000,000 | $0 | - |
| Net Long Term Debt Issuance | $-164,640 | $0 | - |
| Long Term Debt Payments | $-164,640 | $0 | - |
| Net PPE Purchase And Sale | $-437,176 | $-120,877 | $-232,307 |
| Purchase Of PPE | $-437,176 | $-120,877 | $-232,307 |
| Interest Paid Cfo | $-24,105 | $0 | - |
| Change In Working Capital | $1,178,101 | $438,095 | $-694,326 |
| Change In Other Working Capital | $-724,354 | - | $-864,661 |
| Change In Other Current Liabilities | $1,224,416 | $-629,078 | $-415,779 |
| Change In Other Current Assets | $-70,718 | $0 | - |
| Change In Payables And Accrued Expense | $1,775,662 | $784,827 | $137,340 |
| Change In Accrued Expense | $873,273 | $907,859 | $492,871 |
| Change In Payable | $902,389 | $-123,032 | $-355,531 |
| Change In Account Payable | $902,389 | $-123,032 | $-355,531 |
| Change In Receivables | $-1,026,905 | $282,346 | $448,774 |
| Other Non Cash Items | $981,059 | $474,538 | - |
| Stock Based Compensation | $52,663,301 | $18,328,192 | $7,612,530 |
| Depreciation Amortization Depletion | $1,972,554 | $1,876,482 | $1,850,183 |
| Depreciation And Amortization | $1,972,554 | $1,876,482 | $1,850,183 |
| Amortization Cash Flow | $1,578,153 | - | - |
| Amortization Of Intangibles | $1,578,153 | - | - |
| Depreciation | $394,401 | - | - |
| Net Foreign Currency Exchange Gain Loss | $-76,700 | $-732,328 | $508,033 |
| Net Income From Continuing Operations | $-66,613,990 | $-28,132,971 | $-16,544,238 |
| Net Business Purchase And Sale | - | $0 | $-784,124 |
| Purchase Of Business | - | $0 | $-784,124 |
Fetched: 2026-07-09